| Valuation |
9.9 |
auto |
P/E 19.0 |
| Liquidity |
8.3 |
auto |
Current ratio 1.55 |
| Growth |
5.9 |
auto |
Revenue growth 4.7% |
| Profitability |
9.9 |
auto |
Net margin 28.9% |
| Efficiency |
10.0 |
auto |
ROE 40.7% |
| Leadership Tenure |
7.5 |
ai |
CEO Daniel O'Day has led Gilead since March 2019 (~6 years), bringing Roche pharma experience and stable bench including CFO Andrew Dickinson and CMO Merdad Parsey. |
| Ownership Alignment |
4.0 |
auto |
Insider holding 0.13% |
| Strategic Vision |
7.4 |
ai |
Clear pivot from HIV-dominant franchise toward oncology (Trodelvy, Kite/Yescarta) and inflammation, plus the new lenacapavir (Yeztugo) twice-yearly HIV PrEP launch in 2025 represents a credible long-duration roadmap, though oncology execution has been mixed. |
| Focus / Clarity |
7.6 |
ai |
Tightly focused on antivirals (HIV ~70% of revenue via Biktarvy/Descovy), with coherent adjacencies in liver disease, oncology and inflammation under a single biopharma thesis. |
| Diversification |
6.2 |
ai |
Heavy concentration in HIV franchise (~$19B of ~$28B revenue, with Biktarvy alone >$13B); Trodelvy, Veklury and cell therapy provide some balance but HIV patent cliff in early 2030s is the key risk. |
| Maturity / Revenue |
8.6 |
ai |
Revenue $29.4B |
| Growth Potential |
7.4 |
ai |
Lenacapavir/Yeztugo addresses a multi-billion-dollar PrEP TAM with low penetration and could extend HIV franchise into the 2040s; oncology pipeline (Trodelvy, Arcellx anito-cel) and inflammation add optionality, though 2030s HIV LOE caps the upside. |
| Volatility |
5.6 |
auto |
β 0.40 · D/E 112.92 |
| Market Standing |
8.9 |
auto |
Market cap $160.4B |
| Competitive Moat |
8.4 |
ai |
Dominant HIV franchise with >70% global treatment share, deep patent stack on Biktarvy and lenacapavir, regulatory and formulary lock-in, plus Kite's autologous CAR-T manufacturing scale — strong but not best-in-industry. |